Esticast Logo
Get In Touch!

Edaravone Market By End-users ( Clinics, Hospitals ), Industry Trends, Estimation & Forecast, 2017 - 2025

  • Published On: Apr, 2018
  • Category: Healthcare
  • Pages: 148
Edaravone Market is expected to grow with a CAGR of XX% during the forecast period of 2018 to 2025.

Market Overview:

Edaravone is a neuroprotective agent that is mainly available in the global market under the trademark ‘Radicava’ and ‘Radicut’. Since its advent in the late 1980s, edaravone is gaining popularity among patients recovering from stroke and those who are suffering from amyotrophic lateral sclerosis (ALS). Edaravone set foot in the US market in 2017 after the approval of FDA for its use in the treatment of ALS. Similarly, the drug was approved in Japan in June 2015, followed by South Korea in December 2015 for its application in amyotrophic lateral sclerosis treatment. The global edaravone market is expected to witness an impressive growth during the upcoming years due to the unavailability of an approved alternative drug for treating ALS, except riluzole. However, edaravone has proved to be effective in slowly deteriorating the ALS symptoms, which is not the case with riluzole. Riluzole is an effective drug that could only delay death from the disease for several months. As per the data revealed by the Centers for Disease Control and Prevention, each year approximately 12,000-15,000 people are affected with ALS in the United States alone. In addition, nearly 5,000-6,000 new people are diagnosed with amyotrophic lateral sclerosis in the US, every year. Such alarming figures are expected to fuel the growth of global edaravone market during the upcoming years. Moreover, the continuous research and development in the medicine industry is expected to offer lucrative opportunities to the market players in the upcoming years. The report provides detailed qualitative and quantitative analysis of the global edaravone market. Market size and forecast in terms of value and volume has been provided for the period - (2017 - 2025), for the end-user segment in each of the major regions of the world.

Edaravone Market Segmentation

By End-users • Clinics • Hospitals • Others By Geography • North America o U.S. o Canada o Mexico • Europe o U.K o France o Germany o Italy o Spain o Rest of Europe • Asia-Pacific o China o Japan o India o Korea o Rest of APAC • South America o Brazil o Rest of South America • Rest of the World o Middle East o Africa

CHAPTER 1. INTRODUCTION
1.1. RESEARCH METHODOLOGY
1.1.1. ERC desk research
1.1.2. ERC data synthesis
1.1.3. Data validation and market feedback
1.1.4. ERC data sources

CHAPTER 2. EDARAVONE MARKET OVERVIEW
2.1. EDARAVONE MARKET INTRODUCTION
2.2. GLOBAL EDARAVONE MARKET PRODUCTION AND GROWTH RATE, 2017-2025
2.2.1. Global Edaravone Production (VOLUME) and Growth Rate (%), (2017-2025)
2.3. GLOBAL EDARAVONE MARKET CAPACITY AND GROWTH RATE, 2017-2025
2.3.1. Global Edaravone Capacity (VOLUME) and Growth Rate (%), (2017-2025)
2.4. GLOBAL EDARAVONE MARKET REVENUE AND GROWTH RATE, 2017-2025
2.4.1. Global Edaravone Market Revenue (Million USD) and Growth Rate (%), (2017-2025)
2.5. GLOBAL EDARAVONE MARKET CONSUMPTION AND GROWTH RATE, 2017-2025
2.5.1. Global Edaravone Consumption (VOLUME) and Growth Rate (%), (2017-2025)
2.6. GLOBAL EDARAVONE MARKET PRICE TREND, 2017-2025
2.6.1. Global Edaravone Market Price Trend and Growth Rate (%), (2017-2025)

CHAPTER 3. GLOBAL EDARAVONE MARKET BY END-USERS, 2017-2025
3.1. HOSPITALS
3.2. CLINICS
3.3. OTHERS
3.4. GLOBAL EDARAVONE MARKET REVENUE BY END-USERS, 2017-2025
3.4.1. Global Edaravone Market Revenue (Million USD) and Share (%) By End-users, 2017-2025
3.4.2. Hospitals Market Revenue and Growth Rate, 2017-2025
3.4.3. Clinics Market Revenue and Growth Rate, 2017-2025
3.4.4. Others Market Revenue and Growth Rate, 2017-2025
3.5. GLOBAL EDARAVONE MARKET CONSUMPTION BY END-USERS, 2017-2025
3.5.1. Global Edaravone Market Consumption (Volume) and share (%) By End-users, 2017-2025
3.5.2. Hospitals Market Consumption and Growth Rate, 2017-2025
3.5.3. Clinics Market Consumption and Growth Rate, 2017-2025
3.5.4. Others Market Consumption and Growth Rate, 2017-2025

CHAPTER 4. GLOBAL EDARAVONE MARKET BY REGION, 2017-2025
4.1. NORTH AMERICA
4.1.1. U.S.
4.1.2. Canada
4.1.3. Mexico
4.2. EUROPE
4.2.1. U.K.
4.2.2. France
4.2.3. Germany
4.2.4. Italy
4.2.5. Spain
4.2.6. Rest of Europe
4.3. ASIA PACIFIC
4.3.1. China
4.3.2. Japan
4.3.3. India
4.3.4. Korea
4.3.5. Rest of APAC
4.4. SOUTH AMERICA
4.4.1. Brazil
4.4.2. Rest of South America
4.5. REST OF THE WORLD
4.5.1. Middle East
4.5.2. Africa
4.6. GLOBAL EDARAVONE MARKET REVENUE BY REGION, 2017-2025
4.6.1. Global Edaravone Market Revenue (Million USD) and Share (%) By Region, 2017-2025
4.6.2. North America Market Revenue and Growth Rate, 2017-2025
4.6.3. Europe Market Revenue and Growth Rate, 2017-2025
4.6.4. Asia Pacific Market Revenue and Growth Rate, 2017-2025
4.6.5. South America Market Revenue and Growth Rate, 2017-2025
4.6.6. Rest of the World Market Revenue and Growth Rate, 2017-2025

CHAPTER 5. GLOBAL EDARAVONE MARKET PRODUCTION AND CONSUMPTION ANALYSIS BY REGION, 2017-2025
5.1. GLOBAL EDARAVONE MARKET PRODUCTION ANALYSIS BY REGION, 2017-2025
5.1.1. Global Edaravone Market Production (Volume) and Share (%) By Region, 2017-2025
5.1.2. Global Edaravone Market Consumption (Volume) and Share (%) By Region, 2017-2025
5.1.3. North America Market Production and Consumption, 2017-2025
5.1.4. Europe Market Production and Consumption, 2017-2025
5.1.5. Asia Pacific Market Production and Consumption, 2017-2025
5.1.6. South America Market Production and Consumption, 2017-2025
5.1.7. Rest of the World Market Production and Consumption, 2017-2025

CHAPTER 6. MARKET DETERMINANTS
6.1. MARKET DRIVERS
6.2. MARKET RESTRAINTS
6.3. MARKET OPPORTUNITIES
6.4. MARKET DETERMINANTS RADAR CHART

CHAPTER 7. GLOBAL EDARAVONE MARKET COMPETITION BY MANUFACTURERS
7.1. GLOBAL EDARAVONE PRODUCTION AND SHARE BY MANUFACTURERS (2017-2025)
7.1.1. Global Edaravone Production (VOLUME) and Share (%) by Manufacturers (2017-2025)
7.2. GLOBAL EDARAVONE REVENUE AND SHARE BY MANUFACTURERS (2017-2025)
7.2.1. Global Edaravone Revenue (Million USD) and Share (%) by Manufacturers (2017-2025)
7.3. EDARAVONE MARKET COMPETITIVE SITUATION AND TRENDS
7.3.1. Edaravone Market Share (%) of Top 3 Manufacturers
7.3.2. Edaravone Market Share (%) of Top 5 Manufacturers

CHAPTER 8. GLOBAL EDARAVONE MANUFACTURERS ANALYSIS
8.1. MITSUBISHI TANABE PHARMA
8.1.1. Business Overview
8.1.2. Company Basic Information
8.1.3. Edaravone Product Details
8.1.4. Mitsubishi Tanabe Pharma Edaravone Production, Revenue and Gross Margin
8.2. UNICHEM LABORATORIES LTD
8.2.1. Business Overview
8.2.2. Company Basic Information
8.2.3. Edaravone Product Details
8.2.4. Unichem Laboratories Ltd Edaravone Production, Revenue and Gross Margin
8.3. TAJ PHARMACEUTICALS LTD.
8.3.1. Business Overview
8.3.2. Company Basic Information
8.3.3. Edaravone Product Details
8.3.4. Taj Pharmaceuticals Ltd. Edaravone Production, Revenue and Gross Margin
8.4. SIMCERE
8.4.1. Business Overview
8.4.2. Company Basic Information
8.4.3. Edaravone Product Details
8.4.4. Simcere Edaravone Production, Revenue and Gross Margin
8.5. PIRAMAL HEALTHCARE
8.5.1. Business Overview
8.5.2. Company Basic Information
8.5.3. Edaravone Product Details
8.5.4. Piramal Healthcare Edaravone Production, Revenue and Gross Margin
8.6. UCB INDIA LTD
8.6.1. Business Overview
8.6.2. Company Basic Information
8.6.3. Edaravone Product Details
8.6.4. UCB India Ltd Edaravone Production, Revenue and Gross Margin
8.7. SUN PHARMACEUTICAL INDUSTRIES LTD.
8.7.1. Business Overview
8.7.2. Company Basic Information
8.7.3. Edaravone Product Details
8.7.4. Sun Pharmaceutical Industries Ltd. Edaravone Production, Revenue and Gross Margin

CHAPTER 9. EDARAVONE MARKET VALUE CHAIN ANALYSIS
9.1. EDARAVONE INDUSTRIAL CHAIN ANALYSIS
9.2. EDARAVONE KEY RAW MATERIALS ANALYSIS
9.2.1. Key Raw Materials
9.2.2. Price Trend of Key Raw Materials
9.2.3. Key Suppliers of Raw Materials
9.3. MARKETING CHANNEL
9.3.1. Direct Marketing
9.3.2. Indirect Marketing
9.3.3. Distributors/Traders
9.4. CONSUMER ANALYSIS
9.4.1. Consumer 1
9.4.2. Consumer 2
9.4.3. Consumer 3
9.4.4. Consumer 4

• Mitsubishi Tanabe Pharma
• Unichem Laboratories Ltd
• Simcere
• Taj Pharmaceuticals Ltd.
• UCB India Ltd
• Piramal Healthcare
• Sun Pharmaceutical Industries Ltd.

Select License Type

  • $4700
  • $5600
  • $2000
  • Buy Now

Report Highlights:

Complete overview of market
Major drivers, restrain, opportunities, and challenges of the market
Market Trends and how they are boosting the market growth
Changing dynamics in the Market
Complete overview of the market
Historical, Base year, projected, and current market size in terms of value and volume
COVID-19 Impact analysis of the market
Current industry trends and developments

CLIENTS

Esticast Logo

CORPORATE OFFICE

location  (US)

1055 West 7th Street, Los Angeles, CA 90017 (P) US

phone  +1-213-262-0704
location  (APAC Address)

Office No. 407, Navale Icon IT Park, Near Navale Bridge, Narhe, Pune, Maharashtra 411041

phone  +91-959-503-5024

COMPANY

SECURE ONLINE PAYMENTS

  • visa
  • mastercard
  • amex
  • discover

FOLLOW US

  • facebook
  • linkedin
  • phone
  • youtube
© 2022 | All Rights Reserved by Esticast Research & Consulting